Form 4: Orchestra BioMed CEO's Tax Withholding Transaction

Orchestra BioMed Holdings CEO David P. Hochman reported a tax withholding transaction related to restricted stock unit vesting, not a market sale.

Summary

• David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), reported a transaction on September 17, 2025.
• The transaction involved the withholding of shares by the issuer to satisfy tax obligations associated with the vesting of restricted stock units.
• A total of 40,355 shares of Common Stock were withheld from direct ownership at a price of $2.46 per share.
• An additional 3,283 shares of Common Stock were withheld from indirect ownership via the DPH 2008 Trust at a price of $2.46 per share.
• No shares were sold in the open market as a result of this vesting and tax withholding event.
• Following these transactions, David P. Hochman directly beneficially owns 611,105 shares of Common Stock.
• Indirect beneficial ownership through the DPH 2008 Trust stands at 446,048 shares of Common Stock.

Sentiment

Score: 6

Explanation: The transaction is a routine tax withholding event related to executive compensation, not a discretionary sale, which is generally viewed neutrally or slightly positively as it does not signal a lack of confidence from the insider.

Positives

• The transaction was solely for tax withholding purposes related to restricted stock unit vesting, indicating it was not a discretionary sale by the insider.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, which demonstrates a pre-arranged, non-discretionary transaction, reducing concerns about insider trading.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• "Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units."
• "No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations."

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive landscape for Orchestra BioMed Holdings, Inc.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Indirect beneficial ownership of 446,048 shares of Common Stock is held through the DPH 2008 Trust, which is a related party to David P. Hochman.

Stakeholder Impact

• Shareholders receive transparency regarding executive stock ownership changes, confirming a routine tax event rather than a discretionary market sale, which can help maintain investor confidence.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary tax withholding event related to the vesting of restricted stock units for the CEO. It does not indicate any change in the company's fundamentals, management's confidence, or strategic direction. Therefore, it provides no basis for a change in investment recommendation, and a 'hold' stance is appropriate.

Keywords

Orchestra BioMed, OBIO, Form 4, insider transaction, stock withholding, restricted stock units, RSU, David P. Hochman, CEO